Select Cognition Coverage and Published Editorials
AD/PD 2026 | Findings from the Phase 2a SHIMMER trial of zervimesine in mild-to-moderate DLB
Video Journal of Dementia
March 10, 2026
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s
Clinical Trials Arena
By Abigail Beaney
July 30, 2025
New Data: Zervimesine for the Treatment of Dementia with Lewy Bodies and Alzheimer Disease
Psychiatric Times
By Leah Kuntz
July 29, 2025
Zervimesine in Alzheimer’s: Cognition Therapeutics and FDA Discuss Phase 2
Clinical Trial Vanguard
By Jon Napitupulu
July 11, 2025
Cognition soars 35% after positive FDA meeting on Alzheimer’s asset zervimesine
Seeking Alpha
By Jonathan Block
July 10, 2025
Cognition Therapeutics Wraps Up FDA Review, Moves Closer to Phase 3 Alzheimer’s Trial
Prism Marketview
By Alex Corbit
July 10, 2025
Connect with us on Social Media
